The journal of allergy and clinical immunology. In practice
-
J Allergy Clin Immunol Pract · Mar 2016
Multicenter StudySequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated.
Dual treatment with grass and ragweed sublingual immunotherapy (SLIT) tablets has not been studied. ⋯ In this trial, a 4-week sequential SLIT-tablet dosing schedule followed by simultaneous intake of timothy grass and ragweed tablets was well tolerated.
-
J Allergy Clin Immunol Pract · Nov 2014
Multicenter Study Observational StudyA multicenter observational study of US adults with acute asthma: who are the frequent users of the emergency department?
Despite the substantial burden of asthma-related emergency department (ED) visits, there have been no recent multicenter efforts to characterize this high-risk population. ⋯ This multicenter study of US adults with acute asthma demonstrated many frequent ED users and suboptimal preventive management in this high-risk population. Future reductions in asthma morbidity and associated health care utilization will require continued efforts to bridge these major gaps in asthma care.
-
J Allergy Clin Immunol Pract · Sep 2014
Randomized Controlled Trial Multicenter StudyFluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2-agonist vilanterol (VI) is under development for the treatment of asthma and chronic obstructive pulmonary disease. ⋯ Significant improvement in lung function was observed with FF-VI and FF versus placebo in patients with persistent asthma. Improvement of FEV1 when VI was added to FF was not significant. The high placebo response in evening trough FEV1 may have influenced the assessment of efficacy.
-
J Allergy Clin Immunol Pract · Jan 2014
Multicenter StudyOral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.
Peanut allergy creates the risk of life-threatening anaphylaxis that can disrupt psychosocial development and family life. The avoidance management strategy often fails to prevent anaphylaxis and may contribute to social dysfunction. Peanut oral immunotherapy may address these problems, but there are safety concerns regarding implementation in clinical practice. ⋯ Peanut oral immunotherapy carries a risk of systemic reactions. In the context of oral immunotherapy, those reactions were recognized and treated promptly. Peanut oral immunotherapy may be a suitable therapy for patients managed by qualified allergists/immunologists.
-
J Allergy Clin Immunol Pract · Nov 2013
Randomized Controlled Trial Multicenter StudyAnti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial.
Atopic asthma is characterized by Th2 cytokine-driven inflammation of the airway mucosa, which is signaled by the fraction of exhaled nitric oxide (FENO). ⋯ Use of FENO to guide anti-inflammatory treatment within primary care significantly reduced the exacerbation rate and improved asthma symptom control without increasing overall inhaled corticosteroid use.